series-b
Stage
About
Oticara is a clinical-stage biopharmaceutical company developing a novel intranasal corticosteroid therapy for chronic rhinosinusitis, offering physician-administered, targeted, single-dose treatment designed to improve symptoms while minimizing systemic steroid exposure.
Explore Oticara's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.